CHU

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Retrieved on: 
Tuesday, March 19, 2024
Diary, Patient, IND, Adolescence, Pediatrics, Therapy, FAAP, Rett syndrome, Research, Central nervous system, Risk, Webcast, CNS, Ageing, CHU, Safety, AAV, Mutation, Development, MECP2, Disease, Associate, Sleep, Șaeș, Dysrhythmia, FRCP, MTD, Movement, IDMC, VG, Hyperventilation, Principal, Administration, Index, Seizure, CTA, Female, MHRA, Phenotype, ID, Frasier, Pharmaceutical industry

Notably, she has vastly increased interest in social communication and activities at week 35 compared to earlier post-treatment assessments.

Key Points: 
  • Notably, she has vastly increased interest in social communication and activities at week 35 compared to earlier post-treatment assessments.
  • Dr. Schultz is a board-certified, licensed pediatric neurologist experienced in treating patients with Rett syndrome and leading gene therapy clinical trials.
  • She brings more than 17 years of clinical experience and will lead the Company’s clinical development, clinical operations, medical affairs and safety activities.
  • ET to review its financial and operating results and to provide corporate and clinical updates.

BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE

Retrieved on: 
Wednesday, April 3, 2024
Aggression, A9, Immunotherapy, Patent, Infection, Patient, Lung, Neoplasm, Epitope, IMV, FRA, Cancer, Messenger, Bladder cancer, Protein, Trial of the century, CHU, APC, European, Antibody, Immune system, Kidney, Intellectual property, Therapy, Antigen, Peptide, Vaccine

DPX™ is a proprietary lipid-based delivery platform with no aqueous component that can be formulated with a range of packaged antigens, proteins, peptides, mRNA, or small molecules.

Key Points: 
  • DPX™ is a proprietary lipid-based delivery platform with no aqueous component that can be formulated with a range of packaged antigens, proteins, peptides, mRNA, or small molecules.
  • Its unique "no release" mechanism of action allows antigen presenting cells (APCs) to be attracted to the injection site, facilitating a robust and sustained immune response.
  • BioVaxys President and Chief Operating Officer Kenneth Kovan stated "Allowance of this important patent in the United States greatly expands the value of our IP and antigen delivery platform with potential partners.
  • We will be reconvening with the study team at CHU de Québec-Université Laval to plan further development."

InBrain Pharma Announces the Appointment of Dr Véronique Foutel as CEO

Retrieved on: 
Tuesday, February 27, 2024
Mental Health, Health, Neurology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, DBV Technologies, Hospital, Pharmacy, CHU, Dopamine, Growth, Neurological disorder, DSM-IV codes, Entrepreneurship, Pharmaceutical industry, Prevalence, Parkinson's disease, Headquarters, Medicine, Patient, Disease, CSO, Brain

InBrain Pharma, a biotech specialized in brain infusion of drugs for neurological disorder management, today announced the appointment of Dr. Véronique Foutel as CEO to drive the next company's development steps.

Key Points: 
  • InBrain Pharma, a biotech specialized in brain infusion of drugs for neurological disorder management, today announced the appointment of Dr. Véronique Foutel as CEO to drive the next company's development steps.
  • Dr. Matthieu Fisichella, co-founder, and current CEO since 2018, will remain highly committed to InBrain Pharma and become Chief Science Officer.
  • ," says Véronique Foutel, CEO of InBrain Pharma.
  • "I am delighted to hand over the reins to Véronique, whose appointment comes at a critical time for InBrain Pharma.

MEDITWIN Brings Together French Science and Technology Excellence Around Virtual Twins for the Future of Medical Care

Retrieved on: 
Wednesday, January 24, 2024
Data Management, Other Science, Technology, Research, Telemedicine, Virtual Medicine, Manufacturing, Other Health, Apps, Applications, Oncology, Medical Devices, Health Technology, Hospitals, Biometrics, Cardiology, Other Technology, Biotechnology, Software, Health, Science, Electronic Design Automation, PRISM, Teaching hospital, Biology, Morphometrics, Artificial intelligence, Ventricular septal defect, ICM, Thorax, Living Brain, Molina Healthcare, Test management, INRIA, Cerebral atrophy, Foresight, Medicine, Cancer, Algorithm, Risk, Dravet syndrome, Diagnosis, Cardiovascular disease, System, Cardiac arrest, Epilepsy, SAFIR, Alzheimer's disease, Safety, Cognition, CHU, Metabolism, Neurology, Dassault Group, Public, Artificiality, IHU, Hypoplastic left heart syndrome, Mortality, Patient, EEG, Partnership, Consciousness, Ecosystem, Digital, Vascular dementia, PEPR, Biomarker, Medical imaging

MEDITWIN will offer virtual twins for medical practice, helping to improve the quality of care for safer, more accessible healthcare for all.

Key Points: 
  • MEDITWIN will offer virtual twins for medical practice, helping to improve the quality of care for safer, more accessible healthcare for all.
  • The MEDITWIN project will offer personalized virtual twins of organs, metabolism and cancer, for better diagnosis and treatment.
  • Seven new medical practices will be developed from the virtual twins, in neurology, cardiology and oncology.
  • The MEDITWIN public-private alliance is a major step forward, mobilizing the best of medicine, science and technology to serve future healthcare.

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Retrieved on: 
Tuesday, November 14, 2023
CNS, Webcast, Principal, ID, Associate, Gait, Safety, Pediatrics, Gene, Silicon Valley Bank, Socialization, Phenotype, Disease, Risk, Clinical trial, CHU, Administration, Patient, Cell, Dysrhythmia, FAAP, Research, ESGCT, Movement, Posture, Seizure, Hyperventilation, Development, IDMC, FRCP, Rett syndrome, Congress, Central nervous system, Mutation, Walking, Șaeș, AAV, MECP2, Pharmaceutical industry, Nursing, Vaccine, Cryptocurrency, Rett, DALLAS, Neuroscience

Following treatment, both patients experienced improvement in key clinical domains impacting activities of daily living, including breathing dysrhythmia, autonomic function, socialization, and gross and fine motor skills.

Key Points: 
  • Following treatment, both patients experienced improvement in key clinical domains impacting activities of daily living, including breathing dysrhythmia, autonomic function, socialization, and gross and fine motor skills.
  • Additional information on available clinical data is available in the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2023, to be filed with the SEC.
  • Cash and cash equivalents: As of September 30, 2023, the Company had cash and cash equivalents of $164.3 million.
  • Taysha management will hold a conference call and webcast today at 4:30 pm ET to review its financial and operating results and to provide corporate and clinical updates.

GROUNDBREAKING PARTNERSHIP UNVEILED: CANADA'S LEADING PAEDIATRIC HOSPITALS AND THE AZRIELI FOUNDATION JOIN FORCES TO TRANSFORM CHILDREN'S HEALTHCARE IN CANADA

Retrieved on: 
Monday, December 11, 2023
Doctor of Philosophy, Research, DNA, Azrieli Center, Biology, David Azrieli, Hospital, CHU, Genomics, Health, Child, Partnership, Quality of life, Environment, Hospital for Sick Children, Nursing

SickKids and CHU Sainte-Justine are two of North America's largest child health research hospitals, with combined coverage of 61 per cent of Canada's paediatric population.

Key Points: 
  • SickKids and CHU Sainte-Justine are two of North America's largest child health research hospitals, with combined coverage of 61 per cent of Canada's paediatric population.
  • Further, these internationally recognized institutions will focus their ambitions on three innovation pillars: genomics, novel therapies, and rich research data.
  • With these frameworks in place, the Foundation has now invested an additional $50 million to accelerate this transformational vision for personalized child healthcare.
  • "Today marks a pivotal moment in Canadian healthcare history as we embark on a new era of delivering personalized, paediatric care," said Naomi Azrieli, O.C., DPhil, Chair and CEO of the Azrieli Foundation.

Joint announcement from The Hospital for Sick Children, CHU Sainte-Justine and the Azrieli Foundation

Retrieved on: 
Thursday, December 7, 2023
Hospital, Child, CHU, DNA, Senior, Partnership, Azrieli Center, David Azrieli

TORONTO, Dec. 7, 2023 /CNW/ - Senior representatives from Toronto's The Hospital for Sick Children (SickKids), Montreal's CHU Sainte-Justine and the Azrieli Foundation will hold a bilingual media briefing on the Precision Child Health Partnership, the groundbreaking partnership that will revolutionize the future of healthcare for children in Canada.

Key Points: 
  • TORONTO, Dec. 7, 2023 /CNW/ - Senior representatives from Toronto's The Hospital for Sick Children (SickKids), Montreal's CHU Sainte-Justine and the Azrieli Foundation will hold a bilingual media briefing on the Precision Child Health Partnership, the groundbreaking partnership that will revolutionize the future of healthcare for children in Canada.
  • The partnership is made possible by a $50 million investment from the Azrieli Foundation.
  • Media who wish to participate can log-in to the link below or dial-in by using the numbers provided.
  • Media in attendance will be able to ask questions regarding the announcement.

SOPHiA GENETICS Announces Expansion of Work with CHU de Nîmes

Retrieved on: 
Thursday, November 30, 2023
Research, Organization, Bone marrow, CHU, Patient, Medicine, GENETICS, Sophia Genetics, MES, NGS, Hospital, Spectrum, Pharmaceutical industry, Vaccine

BOSTON and ROLLE, Switzerland, Nov. 30, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that it has expanded its work with CHU de Nîmes, a regional and university hospital located in the South of France. The hospital system will use the SOPHiA DDM™ Platform to progress its pharmacogenomics research.

Key Points: 
  • Top researchers from RNPGx member institutions collaborated with SOPHiA GENETICS to develop a pharmacogenomics panel.
  • Additionally, the analytical capabilities of the SOPHiA DDM ™ Platform provide CHU de Nîmes with streamlined insights to facilitate fast and accurate variant discovery and reporting.
  • CHU de Nîmes also uses SOPHiA GENETICS' technology for its research and treatment planning for autism and research of blood cancers.
  • With the expanded relationship, CHU de Nîmes will continue to retain ownership of its research database, building upon the work already done through its use of SOPHiA GENETICS and helping increase the team's expertise in a variety of research areas.

Sun Life and Children's Aid Foundation of Canada partner to improve access to mental health programming for young people in government care

Retrieved on: 
Tuesday, October 10, 2023
Health, Partnership, Family, Dialogue, Children Affected by AIDS Foundation, Kids Help Phone, Organization, Mental health service, Risk, BC Children's Hospital Foundation, Sun Life Financial, Mindfulness, Mental, Mental health, CHU, Trauma, Environment, Medicine, Health Resources and Services Administration, City, Child, Face, Pharmaceutical industry, Nursing

The funding will help launch the Sun Life Bright Futures Kids Wellness Program, a pan-Canadian mental health prevention initiative for young people living in government care.

Key Points: 
  • The funding will help launch the Sun Life Bright Futures Kids Wellness Program, a pan-Canadian mental health prevention initiative for young people living in government care.
  • "Children's Aid Foundation of Canada is doing critical work to expand access to mental health care across the country," said Jacques Goulet, President, Sun Life Canada.
  • "Mental health services have always been especially hard to access for youth involved in the child welfare system.
  • In 2023, Sun Life Canada pledged $3.7 million for youth mental health programming in at-risk or marginalized communities.

Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Retrieved on: 
Tuesday, September 26, 2023
Rett, Index, FRCP, Central nervous system, Pediatrics, Health care, IDMC, MECP2, Rett syndrome, Neuroscience, AAV, CNS, Associate, CHU, FAAP, Clinical trial, Investigational New Drug, Patient, Child, MAD, MTD, Principal, FDA, Safety, IND, MHRA, Pharmaceutical industry

DALLAS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that the second Rett syndrome patient has been dosed with TSHA-102 in the REVEAL Phase 1/2 adult trial in Canada.

Key Points: 
  • DALLAS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that the second Rett syndrome patient has been dosed with TSHA-102 in the REVEAL Phase 1/2 adult trial in Canada.
  • “Dosing the second adult patient in the REVEAL Phase 1/2 adult trial in Canada marks important progress in the ongoing clinical evaluation of TSHA-102 for Rett syndrome,” said Sukumar Nagendran, M.D., President, and Head of R&D of Taysha.
  • The maximum tolerated dose (MTD) or maximum administered dose (MAD) established will then be administered during dose expansion.
  • Enrollment in the low-dose cohort is expected to be complete in the fourth quarter of 2023 with the dosing of the third patient.